Norwegian Contrasts
IC Targets AS is a life-science company dedicated to the development of manganese-based MRI contrast agents and new methods that will improve diagnostic imaging
Norwegian Contrasts
IC Targets AS is a life-science company dedicated to the development of manganese-based MRI contrast agents and new methods that will improve diagnostic imaging
Menu
Norwegian Contrasts
IC Targets AS is a life-science company dedicated to the development of manganese-based MRI contrast agents and new methods that will improve diagnostic imaging
Menu
Norwegian Contrasts
IC Targets AS is a life-science company dedicated to the development of manganese-based MRI contrast agents and new methods that will improve diagnostic imaging
What we do
Mangafodipir is a novel MRI contrast agent in development for improved diagnostics of heart, liver and pancreas diseases.
Recent news
Jul 1, 2025
IC Targets acquires CardiNor AS to strengthen Heart Failure Diagnostics
Jul 1, 2025
IC Targets acquires CardiNor AS to strengthen Heart Failure Diagnostics
Jul 1, 2025
IC Targets acquires CardiNor AS to strengthen Heart Failure Diagnostics
Mar 24, 2025
IC Targets patent approved for granting in Norway
Mar 24, 2025
IC Targets patent approved for granting in Norway
Mar 24, 2025
IC Targets patent approved for granting in Norway
Feb 13, 2025
Phase 2A trial in heart failure: first patients dosed with mangafodipir
Feb 13, 2025
Phase 2A trial in heart failure: first patients dosed with mangafodipir
Feb 13, 2025
Phase 2A trial in heart failure: first patients dosed with mangafodipir
© 2025
Visiting address
c/o ParalleIl, Lørenveien 73A, 0585 Oslo
Contact us
Visiting address
c/o ParalleIl, Lørenveien 73A, 0585 Oslo
Contact us
Visiting address
c/o ParalleIl, Lørenveien 73A, 0585 Oslo
Contact us
© 2025
Visiting address
c/o ParalleIl, Lørenveien 73A, 0585 Oslo
Contact us